| Autor: |
Treshchalin MI; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia., Polozkova VA; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia., Moiseenko EI; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia., Treshalina HM; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia., Shchekotikhin AE; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia.; Organic Chemistry Department, Mendeleyev University of Chemical Technology of Russia, 9 Miusskaya Square, 125047 Moscow, Russia., Pereverzeva ER; Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia. |
| Abstrakt: |
Glycopeptide antibiotics have side effects that limit their clinical use. In view of this, the development of glycopeptides with improved chemotherapeutic properties remains the main direction in the search for new antibacterial drugs. The objective of this study was to evaluate the toxicological characteristics of new semi-synthetic glycopeptide flavancin. Acute and chronic toxicity of antibiotic was evaluated in Wistar rats. The medium lethal dose (LD 50 ) and the maximum tolerated doses (MTD) were calculated by the method of Litchfield and Wilcoxon. In the chronic toxicity study, the treatment regimen consisted of 15 daily intraperitoneal injections using two dosage levels: 6 and 10 mg/kg/day. Total doses were equivalent to MTD or LD 50 of flavancin, respectively. The study included assessment of the body weight, hematological parameters, blood biochemical parameters, urinalysis, and pathomorphological evaluation of the internal organs. The results of the study demonstrated that no clinical-laboratory signs of toxicity were found after 15 daily injections of flavancin at a total dose close to the MTD or LD 50 . The pathomorphological study did not reveal any lesions on the organ structure of animals after low-dose administration of flavancin. Thus, flavancin favorably differs in terms of toxicological properties from the glycopeptides currently used in the clinic. |
